Monday, November 2, 2026

Goldman Sachs And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 12, 2020

Goldman Sachs And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity
Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Seattle Genetics, Inc.

60.8% sales growth and 23.4% return on equity

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. Seattle Genetics, Inc. sales growth this year is expected to be 134.9% and a negative 16.8% for next year. Year-on-year quarterly revenue growth grew by 397.9%, now sitting on 1.86B for the twelve trailing months. Seattle Genetics, Inc.'s sales growth for the next quarter is 60.8%. The company's growth estimates for the present quarter and the next is 478.6% and 72.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.4%.

Seattle Genetics, Inc.'s Stock Top and Bottom Yearly Value

Seattle Genetics, Inc.'s stock is valued at $179.23 at 11:57 EST, way under its 52-week high of $213.94 and way higher than its 52-week low of $90.57.

Seattle Genetics, Inc.'s Moving Average

Seattle Genetics, Inc.'s value is under its 50-day moving average of $179.74 and above its 200-day moving average of $171.22.

2. Goldman Sachs Group, Inc.

12.5% sales growth and 7.31% return on equity

The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment management company worldwide. Goldman Sachs Group, Inc. sales growth this year is anticipated to be 14.8% and a negative 9.5% for next year. Year-on-year quarterly revenue growth grew by 30.8%, now sitting on 39.63B for the twelve trailing months. Goldman Sachs Group, Inc.'s sales growth for the next quarter is 12.5%. The company's growth estimates for the current quarter and the next is 28.6% and 97.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.31%.

Goldman Sachs Group, Inc.'s Stock Top and Bottom Yearly Value

Goldman Sachs Group, Inc.'s stock is valued at $244.40 at 11:57 EST, under its 52-week high of $250.46 and way above its 52-week low of $130.85.

Goldman Sachs Group, Inc.'s Moving Average

Goldman Sachs Group, Inc.'s worth is way higher than its 50-day moving average of $217.32 and way above its 200-day moving average of $207.43.

3. MorphoSys AG

176.1% sales growth and 12.31% return on equity

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. MorphoSys AG sales growth this year is expected to be 361.2% and a negative 31.1% for next year. Year-on-year quarterly revenue growth grew by 76.4%, now sitting on N/A for the twelve trailing months. MorphoSys AG's sales growth for the next quarter is 176.1%. The company's growth estimates for the current quarter and the next is a negative 0% and 61.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.31%.

MorphoSys AG's Stock Top and Bottom Yearly Value

MorphoSys AG's stock is valued at $27.43 at 11:57 EST, way below its 52-week high of $37.96 and way higher than its 52-week low of $18.21.

MorphoSys AG's Moving Average

MorphoSys AG's value is above its 50-day moving average of $26.60 and way below its 200-day moving average of $30.49.

4. Lakeland Industries, Inc.

18.9% sales growth and 21.74% return on equity

Lakeland Industries, Inc. manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide. Lakeland Industries, Inc. sales growth this year is expected to be 37.7% and a negative 11.8% for next year. Year-on-year quarterly revenue growth grew by 27.5%, now sitting on 136.26M for the twelve trailing months. Lakeland Industries, Inc.'s sales growth is a negative 0% for the ongoing quarter and 18.9% for the next. The company's growth estimates for the ongoing quarter and the next is 278.6% and 193.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.74%.

Lakeland Industries, Inc.'s Stock Top and Bottom Yearly Value

Lakeland Industries, Inc.'s stock is valued at $20.40 at 11:57 EST, way under its 52-week high of $28.00 and way above its 52-week low of $9.97.

Lakeland Industries, Inc.'s Moving Average

Lakeland Industries, Inc.'s worth is under its 50-day moving average of $21.67 and under its 200-day moving average of $21.05.
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,533 source documents archived
Query this data → isubstrate.com